What question did this study set out to answer?

This analysis investigates the association between crizanlizumab use and thrombotic events in sickle cell disease patients.

December 8, 2025BloodOpen Access

Thrombotic outcomes in sickle cell disease patients treated with crizanlizumab with or without hydroxyurea: A real-world retrospective cohort analysis using the trinetx database

View Full Paper

Ask AI

Bookmark

Authors

Real-world analysis reveals crizanlizumab increases thrombotic events in sickle cell disease patients, suggesting caution in safety profiles.

This analysis investigates the association between crizanlizumab use and thrombotic events in sickle cell disease patients.
Conducted a retrospective cohort study using TriNetX database of electronic medical records.
Included adult patients with HbSS genotype and documented vaso-occlusive crises.
Performed propensity score matching to balance cohorts based on demographics and hydroxyurea use.
Primary outcome measured was the incidence of thrombotic events at multiple intervals.
1,816 patients met inclusion criteria with equal matched cohorts of 908.
Crizanlizumab patients had higher thrombotic event rates at all monitored time points (RRs 2.15 to 2.32).
Statistical analyses yielded significant p-values (< 0.001) across all time points.

Jabiri et al. (2025) studied this question.

View Full Paper

Ask AI

Bookmark

Real-world analysis reveals crizanlizumab increases thrombotic events in sickle cell disease patients, suggesting caution in safety profiles.